Gainers

• Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million.
• Nkarta (NASDAQ:NKTX) stock increased by 8.67% to $1.88. The company's market cap stands at $112.4 million. As per the news, the Q3 earnings report came out yesterday.
• Polyrizon (NASDAQ:PLRZ) stock rose 7.85% to $12.5. The company's market cap stands at $28.1 million.
• SAB Biotherapeutics (NASDAQ:SABS) shares rose 5.28% to $3.19. The market value of their outstanding shares is at $267.4 million. As per the news, the Q3 earnings report came out yesterday.
• Faeth Therapeutics (NASDAQ:FTH) shares moved upwards by 3.99% to $22.93. The market value of their outstanding shares is at $513.5 million. The company's, Q3 earnings came out 3 days ago.
• Neumora Therapeutics (NASDAQ:NMRA) stock rose 3.31% to $0.52. The market value of their outstanding shares is at $91.5 million.

Losers

• Enliven Therapeutics (NASDAQ:ELVN) shares decreased by 5.5% to $46.74 during Friday's after-market session. The company's market cap stands at $3.1 billion. As per the news, the Q3 earnings report came out yesterday.
• Virax Biolabs Group (NASDAQ:VRAX) shares decreased by 5.3% to $0.75.
• BeOne Medicines (NASDAQ:ONC) shares fell 4.85% to $387.25. The market value of their outstanding shares is at $43.8 billion. As per the press release, Q3 earnings came out yesterday.
• National Healthcare (AMEX:NHC) shares decreased by 4.66% to $198.5. The market value of their outstanding shares is at $3.2 billion. The company's, Q3 earnings came out today.
• Lakewood-Amedex (NASDAQ:LABT) shares declined by 3.97% to $0.37. The company's market cap stands at $1.2 million.
• Jaguar Health (NASDAQ:JAGX) shares fell 3.52% to $0.39. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.